Recombinant Human Anti-EGFR Antibody (Matuzumab) (CAT#: PABX-051)

Figure 1 Effects of cetuximab or matuzumab alone on EGF-induced phosphorylation of (A) EGFR (Tyr845, Tyr992, Tyr1045 eTyr1068).

Effects of cetuximab or matuzumab alone on EGF-induced phosphorylation of (A) EGFR (Tyr845, Tyr992, Tyr1045 eTyr1068 on A431 cells by Western Blotting as described undermaterial and methods.

Meira, D. D., Nóbrega, I., de Almeida, V. H., Mororó, J. S., Cardoso, A. M., Silva, R. L., ... & Ferreira, C. G. (2009). Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. European journal of cancer, 45(7), 1265-1273.

Figure 2 Matuzumab fails to induce chemo/radio sensitization of A431, Caski and C33A gynecological cancer cell lines.

(A) EGFR expression detected by Matuzumab on FACS analysis of A431, Caski and C33A cells, Student's t test * P < 0.05, when compared to controls.

Meira, D. D., Almeida, V. H., Mororó, J. S., Caetano, M. S., Nóbrega, I. P., Batista, D., ... & Ferreira, C. G. (2011). Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab. Molecular cancer, 10(1), 151.

Figure 3 Binding of mAbs cetuximab and matuzumab to peptide arrays.

Binding of mAbs cetuximab and matuzumab to synthetic peptides VLPKTLCGGGS (left) and ACKYPLGHQCGGGS(right) was measured by ELISA by adding serial dilutions of cetuximab, matuzumab or anti-ErbB2 mAb trastuzumab as control totriplicate samples of immobilized peptides (c). Data are represented as mean±s.d.

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517.

Figure 4 Anti-peptide antibodies bind to the surface of EGFR-expressing cells.

Renca-lacZ/EGFR cells were incubated with rabbitanti-KTL peptide antibodies generated by immunization with synthetic peptide VLPKTLCGGGS (a). Control cells were incubatedwith matuzumab, pre-immune rabbit serum or anti-peptide antibodies pretreated with a 40-fold molar excess of specific peptide asindicated. Bound antibodies were detected with FITC-conjugated anti-rabbit IgG (anti-peptide antibodies) or anti-human IgG(matuzumab). Cell bodies were visualized by staining with an excess of propidium iodide (PI).

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517.

Figure 5 Anti-peptide antibodies block ligand binding to EGFR and inhibit the growth of EGFR-overexpressing tumor cells.

Inhibitionof tumor cell growth by anti-peptide antibodies (c). Triplicate samples of A431 and MDA-MB468 cells were incubated with 50 mg/ml ofanti-KTL or anti-YPLG peptide antibodies, or matuzumab, trastuzumab or pre-immune serum as indicated. The relative number ofviable cells in comparison to PBS-treated controls was determined after 70 h in MTT cell viability assays. Representative data from oneof two independent experiments are shown. Statistically significant differences between PBS-treated group and groups treated withantibodies are indicated. ***Po0.001; **Po0.01; NS, P40.05. Data are represented as mean±s.d.

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517.